This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Medicinal Bioconvergence Research Center. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Semi Lim: Innovator in Anticancer Research
Introduction
Semi Lim is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer research, particularly through his innovative methods for screening anticancer agents.
Latest Patents
Semi Lim holds a patent for a method that screens anticancer agents inhibiting the binding of AIMP2-DX2 and HSP70. This invention relates to a method for identifying anticancer agents that can effectively prevent the progression of cancer by inhibiting the expression of HSP70 or the binding of HSP70 and AIMP2-DX2. The pharmaceutical composition derived from this method can be instrumental in developing effective cancer treatments.
Career Highlights
Throughout his career, Semi Lim has worked at various esteemed institutions, including the Medicinal Bioconvergence Research Center and the Medical Bioconvergence Research Center. His work has focused on advancing the understanding and treatment of cancer through innovative research.
Collaborations
Semi Lim has collaborated with notable colleagues such as Sunghoon Kim and Dae Gyu Kim. Their combined efforts have contributed to the advancement of cancer research and the development of new therapeutic strategies.
Conclusion
Semi Lim's innovative work in anticancer research highlights his commitment to improving cancer treatment methodologies. His contributions are paving the way for future advancements in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile